Spots Global Cancer Trial Database for pd1
Every month we try and update this database with for pd1 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung Cancer | NCT03755115 | Small Cell Lung... | Epirubicin plus... | 18 Years - 75 Years | Henan Cancer Hospital | |
| Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756) | NCT03725059 | Breast Cancer | Pembrolizumab (... Placebo (P) Paclitaxel (X) Doxorubicin (A) Epirubicin (E) Cyclophosphamid... Endocrine thera... Radiation thera... Surgery | 18 Years - | Merck Sharp & Dohme LLC | |
| Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | NCT03212404 | Lung Neoplasms Carcinoma, Non-... Carcinoma, Smal... Malignant Mesot... Head and Neck C... Melanoma Merkel Cell Car... Renal Cell Carc... Urothelial Carc... Classical Hodgk... Cutaneous Squam... Non Hodgkin Lym... Endometrial Can... | CK-301 (cosibel... | 18 Years - | Checkpoint Therapeutics, Inc. | |
| Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence | NCT04782804 | Cholangiocarcin... | Capecitabine PD-1 Antibody（T... | 18 Years - 75 Years | Fudan University | |
| Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062) | NCT03099161 | Neoplasm | preladenant pembrolizumab | 18 Years - | Merck Sharp & Dohme LLC | |
| Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183) | NCT02576977 | Multiple Myelom... | Pembrolizumab Pomalidomide Dexamethasone | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma | NCT03445533 | Metastatic Mela... | Ipilimumab Tilsotolimod wi... | 18 Years - | Idera Pharmaceuticals, Inc. | |
| Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189) | NCT02578680 | Non-Small-Cell ... | Pembrolizumab 2... Cisplatin Carboplatin Pemetrexed Folic acid 350-... Vitamin B12 100... Dexamethasone 4... Saline solution | 18 Years - | Merck Sharp & Dohme LLC | |
| Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | NCT03212404 | Lung Neoplasms Carcinoma, Non-... Carcinoma, Smal... Malignant Mesot... Head and Neck C... Melanoma Merkel Cell Car... Renal Cell Carc... Urothelial Carc... Classical Hodgk... Cutaneous Squam... Non Hodgkin Lym... Endometrial Can... | CK-301 (cosibel... | 18 Years - | Checkpoint Therapeutics, Inc. | |
| SHR-1210 Combined With Epirubicin in the Treatment of Extensive Disease Small Cell Lung Cancer | NCT03755115 | Small Cell Lung... | Epirubicin plus... | 18 Years - 75 Years | Henan Cancer Hospital | |
| Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence | NCT04782804 | Cholangiocarcin... | Capecitabine PD-1 Antibody（T... | 18 Years - 75 Years | Fudan University | |
| Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598) | NCT03302234 | Carcinoma, Non-... | Pembrolizumab Ipilimumab Placebo | 18 Years - | Merck Sharp & Dohme LLC | |
| Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161) | NCT03407170 | Advanced Melano... | pembrolizumab | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of CDX-585 in Patients With Advanced Malignancies | NCT05788484 | Non-small Cell ... Gastric Cancer Head and Neck C... Ovarian Cancer Primary Periton... Fallopian Tube ... Bladder Urothel... Colorectal Canc... Esophageal Canc... Hepatic Cancer Renal Cell Carc... Cholangiocarcin... Pancreatic Canc... Other Solid Tum... | CDX-585 | 18 Years - | Celldex Therapeutics | |
| Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042) | NCT02220894 | Non-small Cell ... | pembrolizumab carboplatin paclitaxel pemetrexed | 18 Years - | Merck Sharp & Dohme LLC | |
| Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001) | NCT03564691 | Neoplasms | MK-4830 Pembrolizumab Carboplatin Pemetrexed Lenvatinib Paclitaxel Cisplatin MK-4830A | 18 Years - | Merck Sharp & Dohme LLC | |
| A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors | NCT05396391 | Advanced Malign... | IAP0971 | 18 Years - 80 Years | SUNHO（China）BioPharmaceutical CO., Ltd. | |
| Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189) | NCT02578680 | Non-Small-Cell ... | Pembrolizumab 2... Cisplatin Carboplatin Pemetrexed Folic acid 350-... Vitamin B12 100... Dexamethasone 4... Saline solution | 18 Years - | Merck Sharp & Dohme LLC | |
| AB154 Combined With AB122 for Recurrent Glioblastoma | NCT04656535 | Glioblastoma | AB122 AB154 Placebo | 18 Years - | Yale University | |
| The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC | NCT04338399 | Head and Neck C... | Buparlisib & Pa... | 18 Years - | Adlai Nortye Biopharma Co., Ltd. | |
| Study of Pembrolizumab (MK-3475) in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-025/KEYNOTE-025) | NCT02007070 | Non-small Cell ... | Pembrolizumab | 20 Years - | Merck Sharp & Dohme LLC | |
| A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061) | NCT02370498 | Gastric Adenoca... Gastroesophagea... | pembrolizumab paclitaxel | 18 Years - | Merck Sharp & Dohme LLC | |
| Safety and Efficacy Study of Pembrolizumab (MK-3475) in Chinese Participants With Locally Advanced or Metastatic Melanoma (MK-3475-151/KEYNOTE-151) | NCT02821000 | Melanoma | Pembrolizumab | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407) | NCT02775435 | Non-small Cell ... | Pembrolizumab Paclitaxel Nab-paclitaxel Carboplatin Saline placebo ... | 18 Years - | Merck Sharp & Dohme LLC | |
| Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme | NCT03170141 | Glioblastoma Mu... Glioblastoma Mu... | Antigen-specifi... | 1 Year - 80 Years | Shenzhen Geno-Immune Medical Institute | |
| Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study | NCT03950674 | Non-Small-Cell ... | Pembrolizumab 2... Cisplatin Carboplatin Pemetrexed Folic acid 350-... Vitamin B12 100... Dexamethasone 4... Saline solution | 18 Years - | Merck Sharp & Dohme LLC | |
| Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041) | NCT02180061 | Melanoma | Pembrolizumab | 20 Years - | Merck Sharp & Dohme LLC | |
| Effect of Compound Kushen Injection Combined With Pabolizumab in the Treatment of Cervical Adenocarcinoma | NCT05259540 | Cervical Cancer | compound kushen... | 18 Years - 75 Years | Women's Hospital School Of Medicine Zhejiang University | |
| Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) | NCT03036488 | Triple Negative... | Pembrolizumab Carboplatin Paclitaxel Doxorubicin Epirubicin Cyclophosphamid... Placebo Granulocyte col... | 18 Years - | Merck Sharp & Dohme LLC | |
| Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence | NCT04782804 | Cholangiocarcin... | Capecitabine PD-1 Antibody（T... | 18 Years - 75 Years | Fudan University | |
| Study of MK-1248 With and Without Pembrolizumab (MK-3475) for Participants With Advanced Solid Tumors (MK-1248-001) | NCT02553499 | Advanced Solid ... | MK-1248 pembrolizumab | 18 Years - | Merck Sharp & Dohme LLC | |
| Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence | NCT04782804 | Cholangiocarcin... | Capecitabine PD-1 Antibody（T... | 18 Years - 75 Years | Fudan University | |
| The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC | NCT04338399 | Head and Neck C... | Buparlisib & Pa... | 18 Years - | Adlai Nortye Biopharma Co., Ltd. | |
| Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394) | NCT03062358 | Carcinoma, Hepa... | pembrolizumab placebo best supportive... | 18 Years - | Merck Sharp & Dohme LLC | |
| Study of Pembrolizumab (MK-3475) in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-025/KEYNOTE-025) | NCT02007070 | Non-small Cell ... | Pembrolizumab | 20 Years - | Merck Sharp & Dohme LLC | |
| Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789) | NCT03515837 | Non-small Cell ... | pembrolizumab pemetrexed carboplatin cisplatin saline solution | 18 Years - | Merck Sharp & Dohme LLC | |
| Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161) | NCT03407170 | Advanced Melano... | pembrolizumab | 18 Years - | Merck Sharp & Dohme LLC | |
| Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012) | NCT01848834 | Cancer Solid Tumor | Pembrolizumab | 18 Years - | Merck Sharp & Dohme LLC | |
| Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555) | NCT03665597 | Melanoma | Pembrolizumab D... Pembrolizumab D... Pembrolizumab D... Pembrolizumab D... | 18 Years - | Merck Sharp & Dohme LLC | |
| Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy | NCT05977673 | Hodgkin Lymphom... | Tislelizumab | 65 Years - | Fondazione Italiana Linfomi - ETS | |
| Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) | NCT03486873 | Solid Tumors Hematologic Mal... | Pembrolizumab Standard of Car... Lenvatinib | 18 Years - | Merck Sharp & Dohme LLC | |
| Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789) | NCT03515837 | Non-small Cell ... | pembrolizumab pemetrexed carboplatin cisplatin saline solution | 18 Years - | Merck Sharp & Dohme LLC | |
| GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers | NCT03198052 | Lung Cancer Cancer Immunotherapy CAR-T Cell | CAR-T cells tar... | 18 Years - 75 Years | Second Affiliated Hospital of Guangzhou Medical University | |
| A Study of CDX-585 in Patients With Advanced Malignancies | NCT05788484 | Non-small Cell ... Gastric Cancer Head and Neck C... Ovarian Cancer Primary Periton... Fallopian Tube ... Bladder Urothel... Colorectal Canc... Esophageal Canc... Hepatic Cancer Renal Cell Carc... Cholangiocarcin... Pancreatic Canc... Other Solid Tum... | CDX-585 | 18 Years - | Celldex Therapeutics | |
| Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426) | NCT02853331 | Renal Cell Carc... | Pembrolizumab Axitinib Sunitinib | 18 Years - | Merck Sharp & Dohme LLC | |
| Effect of Compound Kushen Injection Combined With Pabolizumab in the Treatment of Cervical Adenocarcinoma | NCT05259540 | Cervical Cancer | compound kushen... | 18 Years - 75 Years | Women's Hospital School Of Medicine Zhejiang University | |
| A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407) | NCT02775435 | Non-small Cell ... | Pembrolizumab Paclitaxel Nab-paclitaxel Carboplatin Saline placebo ... | 18 Years - | Merck Sharp & Dohme LLC | |
| Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630) | NCT03833167 | Carcinoma, Squa... | Pembrolizumab 4... Placebo | 18 Years - | Merck Sharp & Dohme LLC | |
| Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042) | NCT02220894 | Non-small Cell ... | pembrolizumab carboplatin paclitaxel pemetrexed | 18 Years - | Merck Sharp & Dohme LLC | |
| A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013) | NCT01953692 | Myelodysplastic... Multiple Myelom... Hodgkin Lymphom... Non-Hodgkin Lym... Diffuse Large B... Follicular Lymp... Primary Mediast... | Pembrolizumab Lenalidomide 20... Lenalidomide 25... | 18 Years - | Merck Sharp & Dohme LLC | |
| Effect of Compound Kushen Injection Combined With Pabolizumab in the Treatment of Cervical Adenocarcinoma | NCT05259540 | Cervical Cancer | compound kushen... | 18 Years - 75 Years | Women's Hospital School Of Medicine Zhejiang University | |
| Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | NCT03212404 | Lung Neoplasms Carcinoma, Non-... Carcinoma, Smal... Malignant Mesot... Head and Neck C... Melanoma Merkel Cell Car... Renal Cell Carc... Urothelial Carc... Classical Hodgk... Cutaneous Squam... Non Hodgkin Lym... Endometrial Can... | CK-301 (cosibel... | 18 Years - | Checkpoint Therapeutics, Inc. | |
| Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412) | NCT03040999 | Head and Neck N... | Pembrolizumab Placebo Cisplatin Accelerated Fra... Standard Fracti... | 18 Years - | Merck Sharp & Dohme LLC | |
| Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087) | NCT02453594 | Hodgkin Lymphom... | pembrolizumab | 18 Years - | Merck Sharp & Dohme LLC |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
